Trial Profile

A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda) in Subjects With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tivozanib (Primary) ; Capecitabine
Indications Advanced breast cancer; Colorectal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors AVEO Oncology

Most Recent Events

23 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
22 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
04 Jun 2012 Additional lead trial investigator (Shefali Agarwal) identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com